Filter News

VisionCare Ophthalmic Technologies Announces Presentations At The Annual Meeting Of The American Society of Cataract & Refractive Surgery

Published: Mar 17, 2006

SARATOGA, Calif., March 17 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), announced today three presentations on its platform technology are scheduled at the upcoming annual symposium of the American Society of Cataract and Refractive Surgery (ASCRS) March 18 - 21, 2006, in San Francisco. Podium presentations are scheduled at the Moscone Convention Center as follows:

Clinical Trial Presentations -- Saturday, March 18, 1:07 PM, Moscone Room 301 Implantable Miniature Telescope in Patients with ARMD: Final Assessment of Surgical Technique from the Phase II/III Trial Mark Packer, MD -- Monday, March 20, 1:32 PM, Moscone Room 110 Implantable Miniature Telescope in Patients with Macular Degeneration: 1-Year Results R. Doyle Stulting, MD, PhD Preclinical Study Presentation -- Saturday, March 18, 1:02 PM, Moscone Room 301 Preclinical Studies of Implantable Miniature Telescope for Pseudophakic Eyes Ehud I. Assia, MD

At ASCRS, VisionCare is located in Booth #3139 at the Moscone Convention Center in San Francisco.

About the Visual Prosthetic Device

The investigational Implantable Miniature Telescope (IMT(TM) by Dr. Isaac Lipshitz) is designed to be a permanent solution for moderate to profound vision loss due to advanced, end-stage forms of AMD that have no current surgical or medical treatment options. Smaller than a pea, the telescope prosthetic device is implanted in one eye in an outpatient surgical procedure. In the implanted eye, the device renders enlarged central vision images over a wide area of the retina to improve central vision, while the non-operated eye provides peripheral vision for mobility and orientation.

The prospective IMT002 Phase II/III trial, evaluating the safety and efficacy of VisionCare's investigational device in individuals with moderate to profound bilateral central vision impairment associated with end-stage AMD, is complete. The trial enrolled over 200 patients at 28 leading medical universities and ophthalmic centers across the country. VisionCare has submitted a Premarket Approval (PMA) Application which seeks regulatory approval for the telescope prosthetic device to treat central vision loss due to advanced, irreversible forms of AMD. The Food and Drug Administration (FDA) has assigned the application expedited review status.

About Macular Degeneration

Macular degeneration is a disorder of the central retina, or macula, which is responsible for detailed vision that controls important functional visual activities like reading, recognizing faces, and watching television. According to the National Eye Institute over 1.7 million Americans over age 50 suffer mild to profound vision loss from advanced AMD, which culminates as end-stage AMD. Approximately half of the individuals living with advanced AMD are affected in both eyes.

About VisionCare

VisionCare Ophthalmic Technologies, Inc., headquartered in Saratoga, CA is a privately-held company focused on development, manufacturing, and marketing of visual prosthetic devices. The Implantable Miniature Telescope was invented by company founders, Isaac Lipshitz, M.D. and Yossi Gross. Information on VisionCare can be found at www.visioncareinc.net.

VisionCare Ophthalmic Technologies, Inc.

CONTACT: Allen Hill, President and CEO of VisionCare OphthalmicTechnologies, Inc., +1-408-872-9393, or mail@visioncareinc.net

Back to news